Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Registration Number
- NCT03385382
- Lead Sponsor
- G. d'Annunzio University
- Brief Summary
Between December 2016 and June 2017 a total of 40 eyes from 40 diabetic retinopathy patients with diabetic macular edema were recruited at the Ophthalmologic Clinic of University "G. d'Annunzio", Chieti-Pescara, Italy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Age >18 years old
- BCVA greater than 0.5 LogMAR in the study eye at baseline examination
- Presence of recent DME
- CMT > 300µm as measured using the SD-OCT at the baseline examination
Exclusion Criteria
- Any previous ocular surgery in the last 6 months
- Laser treatments
- Prior ocular trauma
- Retinal vascular diseases
- Vitreo-retinal interface diseases
- Medium lens opacities (according to Lens Opacities Classification System)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description ranibizumab Ranibizumab Injection Patients with diabetic macular edema receiving ranibizumab Dexamethasone group Dexamethasone intravitreal implant 0.7 mg Patients with diabetic macular edema receiving dexamethasone
- Primary Outcome Measures
Name Time Method Central macular thickness 6 months Decrease of macular thickness
- Secondary Outcome Measures
Name Time Method visual acuity 6 months Increase of mean visual acuity